Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “PILOCARPINE”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 325 records · Page 18Linked to original sources

Chronic lithium treatment inhibits pilocarpine-induced mossy fiber sprouting in rat hippocampus.

Lithium remains the gold standard in the treatment of bipolar disorder. Long-term treatment with lithium may lead to specific adaptational changes in gene expression that contribute to a neuroprotective effect. In this study, the pilocarpine model of spontaneous limbic epilepsy was used to induce mossy fiber sprouting (axonal growth of the dentate granule cells that synapse on the pyramidal cells of the CA3 region) to examine the prophylactic neuroprotective effects of lithium in vivo. There were four groups of animals: pilocarpine treated (Pil+/Li-); pilocarpine treated followed by lithium (Pil+/Li+); lithium alone (Pil-/Li+); control (Pil-/Li-). Timm staining was used to obtain density measurements in the stratum oriens and the inner molecular layer of the hippocampus. Mossy fiber density was higher in the pilocarpine-treated animals compared to controls. Chronic lithium following pilocarpine treatment attenuated the density of mossy fibers but lithium alone had no effect. No changes in hilar volume or neuronal number were detected using stereological procedures. The ability of lithium to attenuate activation-induced reorganization in the hippocampus provides evidence for its role as a neuroprotective agent in an in vivo model that may be relevant to its clinical effects in bipolar disorder.

Animals↗

Pilocarpine-induced cholinergic sweat secretion compared with emotional sweat secretion in atopic dermatitis.

We studied pilocarpine-induced cholinergic sweating, emotional sweating and sympathetic reflex sweating in atopic dermatitis (AD) patients. Secreted sweat was measured both with equipment that continuously records sweat rate and with a filter paper method that measures sweat weight absorbed. Comparison of the two methods revealed that the filter paper method underestimated the sweat secretion in AD patients. While AD patients showed no significant abnormalities in emotional sweating and sympathetic reflex sweating, the duration of pilocarpine-induced sweating was prolonged. The time from the maximal sweat rate until the sweat rate fell to half of the maximal rate was significantly longer in AD patients than in control subjects. In contrast, the time from the beginning of sweat secretion until the maximal sweat rate was not significantly different between AD patients and control subjects. There was no significant difference between AD patients and control subjects in sweat volume secreted in 20 min after pilocarpine iontophoresis. In AD patients, the total sweat volume secreted after pilocarpine iontophoresis was greater than in control subjects, although not significantly. These results suggest that the system of deactivation of pilocarpine-induced sweat secretion is impaired in AD patients whereas the activation system is not altered.

Adult↗

[The effect of unintentional overdoses of pilocarpine on pulmonary surfactant in mice].

Pilocarpine, used in the treatment of glaucoma, shows basically parasympathomimetic activities and in contrast to choline derivatives an extremely potent effect on salivary and sweat glands and a noticeable increase of bronchial secretion. Investigations were carried out in mice to determine whether the administration of pilocarpine results in an increase of bronchial secretion as such or whether it likewise influences the secretion of surfactant, i.e., the phospholipoprotein responsible for the stability of the alveoli. Our experiments (P/V diagrams and histochemical staining) demonstrate that pilocarpine decreases the secretion of pulmonary surfactant. When pilocarpine and Ambroxol are administered the effects on the two parameters are similar to the controls. In other words, Ambroxol increases the secretion of surfactant even in cases of intoxication with pilocarpine.

Ambroxol↗

Malnutrition and REM-sleep deprivation modulate in rats the impairment of spreading depression by a single sub-convulsing dose of pilocarpine.

This study aimed to investigate the effect of a single injection of pilocarpine upon the phenomenon of cortical spreading depression (SD), in adult rats submitted to early malnutrition and/or to REM-sleep deprivation for 72h prior to the SD-recordings. The SD was recorded continuously for 3-4h in 13 well-nourished (W) and 15 early-malnourished (M) adult rats. One to two hours after the beginning of the recording session, a sub-convulsing intraperitoneal (i.p.) injection of pilocarpine (190mg/kg) was applied and its effects on SD were studied during the rest of the recording session. Pilocarpine reduced markedly the ECoG amplitudes in all animals and decreased the SD velocity of propagation in the M-, but not in the W-rats, as compared with the pre-drug values for the same animals. In additional 9W- and 10 M-animals, REM-sleep deprivation was induced during the 72 h preceding the SD-recording session. This condition enhanced the pilocarpine effects on SD in the W-, but not in the M-rats, as compared to the respective non-deprived (ND) groups. The results indicate an important acute cholinergic influence on SD, acting by means of pilocarpine-activated muscarinic receptors. This effect seems to be differentially modulated by sleep deprivation and malnutrition.

Animals↗

Stability of pilocarpine ophthalmic solutions.

The stability of pilocarpine and pilocarpine-timolol eyedrop preparations available on the Argentine market was studied. A high-performance liquid chromatographic method that allows the estimation of pilocarpine in the presence of degradation products was used for the study according to the preestablished design. It was found that pilocarpine solutions are stable, while pilocarpine in association with timolol shows significant degradation.

Argentina↗

Influence of hydroxypropyl beta-cyclodextrin on the corneal permeation of pilocarpine.

The influence of hydroxypropyl beta-cyclodextrin (HPbetaCD) on the corneal permeation of pilocarpine nitrate was investigated by an in vitro permeability study using isolated rabbit cornea. Pupillary-response pattern to pilocarpine nitrate with and without HPbetaCD was examined in rabbit eye. Corneal permeation of pilocarpine nitrate was found to be four times higher after adding HPbetaCD into the formulation. The reduction of pupil diameter (miosis) by pilocarpine nitrate was significantly increased as a result of HPbetaCD addition into the simple aqueous solution of the active substance. The highest miotic response was obtained with the formulation prepared in a vehicle of Carbopol 940. It is suggested that ocular bioavailability of pilocarpine nitrate could be improved by the addition of HPbetaCD.

2-Hydroxypropyl-beta-cyclodextrin↗

Mechanism of vascular relaxation by cholinomimetic drugs with special reference to pilocarpine and arecoline.

The muscarinic receptor-mediated and non-muscarinic vascular effects of cholinomimetic drugs used in glaucoma were quantified. On the isolated rat aorta, the vascular tone induced by phenylephrine is functionally antagonized by cholinomimetic drugs. Based on EC50, the relative order of potency for the endothelium-dependent vascular relaxation was acetylcholine (0.05 microM) 1 > (+/-)-methacholine (0.35 microM) 1/7 > carbachol (0.63 microM) 1/12 > (+/-)-aceclidine (1.26 microM) 1/25. The maximal effects of the four agonists varied between 82-87%. The muscarinic vascular relaxation of 0.03 microM to 100 microM pilocarpine was less than 15%. At high concentrations, pilocarpine had 1/20.000 the vascular activity of acetylcholine. Physostigmine failed to potentiate the vascular relaxation of exogenous acetylcholine, indicating the absence of acetylcholine esterase in the tissue. Arecoline, with an EC50 of 7.76 microM, was partly sensitive to the removal of the endothelium. Atropine treatment did not block the vascular effect of high concentrations of pilocarpine. Atropine, as expected, blocked the vascular effects of carbachol with K(B) = 3.2 nM. Pilocarpine produces vascular relaxation by its competition with spasmogens like phenylephrine, oxymetazoline, vasopressin or latanoprost. Arecoline also shares these properties with pilocarpine in the blood vessel. The molecular mechanism of the vascular effects as well as ocular clinical implications of cholinomimetic drugs is discussed.

Animals↗

Pilocarpine mydriasis in mice.

In several rodent species pilocarpine and oxotremorine produce mydriasis, rather than the miosis which is characteristic of most other species. We have established that pilocarpine is a mydriatic drug in mice, a species in which the action has previously not been described, and that this effect occurs after local ocular, intraperitoneal (IP) or intracerebroventricular (ICV) application. Arecoline produces miosis or mydriasis (depending on dose) following direct ocular application but mild mydriasis after IP or ICV injection. Atropine also produces mydriasis in mice, and the effect of pilocarpine is additive with that produced by atropine and is not antagonized by antihistamines. Direct ICV pilocarpine injection produces mydriasis at doses equivalent to those used systemically. Pilocarpine mydriasis probably results from inhibition of parasympathetic activity.

Animals↗

The effect of pilocarpine on ocular levobunolol absorption from ophthalmic solutions.

Studies in vitro and in vivo were conducted to investigate the effect of pilocarpine on ocular absorption of levobunolol when both drugs were formulated in one solution dosage. The ocular absorption of levobunolol is pH-dependent. Due to the large buffering capacity of pilocarpine at pH 5.5, the ocular absorption of levobunolol from pilocarpine-containing solutions was reduced by approximately four-fold as compared to a non-pilocarpine-containing formulation at pH 7.2. The ocular absorption of levobunolol in the presence of pilocarpine at acidic pH was enhanced by the use of sulfosuccinates, specifically Schercopol CMS.

Absorption↗

A study of gastric secretion in dogs using pilocarpine.

1 Pilocarpine (40 microgram/min i.v.) stimulated acid and pepsin secretion from Heidenhain pouches but did not stimulate secretion from the innervated stomach. 2 Pilocarpine significantly increased acid secretion from the innervated main stomach after the vagal nerves were bilaterally blocked with lidocaine. 3 The effect of pilocarpine on secretion from the Heidenhain puch was depressed by ganglionic blockade (hexamethonium), by dopamine and by isoprenaline. 4 The stimulatory action of histamine on gastric secretion from either pouch or gastric fistulae was uninfluenced by dopamine. 5 The action of pilocarpine was augmented by the muscarinic ganglionic stimulant AHR 602. Considering this effect, as well as the secretory depression of isoprenaline, pilocarpine resembles pentagastrin rather than methacholine in its action.

Animals↗

Supersensitivity of salivation in response to pilocarpine after withdrawal of chronically administered hyoscine in the mouse.

1. The duration of the effect of a single large dose of hyoscine, in reducing the salivary response of mice to pilocarpine, was established as less than 66 hours.2. Supersensitivity was observed, after daily oral dosing with hyoscine, in the increased salivation of mice in response to pilocarpine injected at least 66 h after withdrawing hyoscine.3. The minimum duration of pretreatment with hyoscine that resulted in supersensitivity was 5 days. The daily dose was more effective if divided.4. The period after withdrawal for which supersensitivity could be detected was 6 days.5. The maximum salivary response to pilocarpine was increased by chronic hyoscine pretreatment.6. The antagonism of a single dose of hyoscine to pilocarpine salivation, as expressed by the dose-ratio of pilocarpine, was not altered by chronic hyoscine pre-treatment.

Animals↗

Mechanism of catecholamine antagonism in rat heart produced by pilocarpine and related drugs.

1 High concentrations of pilocarpine and methacholine consistently lowered the potencies of a series of adrenoceptor agonists as shown by displacement of complete cumulative dose-effect curves for their positive chronotropic action on rat isolated atria. The order of potency of the agonists was characteristic of beta-adrenoceptor activation and this was converted to the type which characterizes alpha-adrenoceptor activation when pilocarpine was present.2 Propranolol effectively blocked the adrenoceptor agonists in the presence of pilocarpine and phentolamine abolished the antagonistic actions of pilocarpine. Atropine, which by itself did not affect the action of the adrenoceptor agonists, abolished both the bradycardia and antagonism produced by pilocarpine.3 It is concluded that pilocarpine antagonizes adrenoceptor agonists by muscarinic cholinoceptor activation without involving classical adrenoceptors.

Animals↗

The effects of acute and chronic lithium treatment on pilocarpine-stimulated phosphoinositide hydrolysis in mouse brain in vivo.

1. Measurements were made of the in vivo formation of inositol phosphates in the brains of C57/B1/601a mice treated acutely or chronically with lithium chloride (LiCl). 2. A single injection of LiCl (10 mEquiv kg-1, s.c.) 18 h before death increased the accumulation of [3H]-inositol phosphates ([3H]-Ins P's) in the brains of mice injected i.c.v. with [3H]-myo-inositol 24 h previously. 3. Pilocarpine (200 mg kg-1, i.p.) injected 15 min before death further enhanced the formation of [3H]-Ins P's in the brains of LiCl-treated, but not saline-treated, mice. The enhancement due to pilocarpine was abolished by injection of atropine sulphate (10 mg kg-1, i.p.) 10 min earlier. 4. Chronic (14 days) LiCl feeding produced an accumulation of [3H]-Ins P's significantly less than that due to a single injection of LiCl, but the response to pilocarpine was markedly greater in mice chronically fed with LiCl when compared with mice acutely injected with LiCl. 5. Mass measurements of endogenous inositol 1,4,5 triphosphate revealed increases due to pilocarpine and chronic LiCl feeding alone. A combination of the two treatments produced levels greater than either alone. 6. These results demonstrate that LiCl treatment enhances both basal and pilocarpine-stimulated inositol phospholipid hydrolysis in vivo and this might be relevant to its therapeutic effects.

Animals↗

Consequences of prolonged caffeine administration and its withdrawal on pilocarpine- and kainate-induced seizures in rats.

PURPOSE: To investigate the consequences of caffeine consumption on epileptic seizures, we used the pilocarpine and the kainate models of epilepsy. We hypothesized that prolonged caffeine consumption or its withdrawal would alter adenosine levels and hence alter seizure susceptibility. METHODS: We administered a 0.1% caffeine solution in the drinking water of adult male Wistar rats over a 2-week period. We challenged another group of animals with the same doses of pilocarpine or kainate 12 h after the withdrawal of the same caffeine-administration protocol. RESULTS: This did not alter the threshold for the induction of seizures by a subconvulsant dose of pilocarpine (200 mg/kg, i.p.) or kainic acid (8 mg/kg, i.p.). Similarly, challenging another group of animals with the same doses of pilocarpine or kainate 12 h after the withdrawal of the same caffeine-administration protocol did not lead to any significant changes in seizures. CONCLUSIONS: With the pilocarpine model of epilepsy, we were not able to find any significant difference in seizure profile that could stem from either caffeine administration or its withdrawal. Despite the extensive laboratory evidence on the convulsant properties of xanthine derivatives in animal models of epilepsy, such strong evidence is lacking in clinical settings. Our current findings with the administration of caffeine at doses similar to those of daily life both support and confirm the clinical experience.

Adenosine↗

Substantia nigra is an anticonvulsant site of action of topiramate in the focal pilocarpine model of limbic seizures.

PURPOSE: The substantia nigra pars reticulata (SNR) is known to play a role in gating and control of seizures. Prompted by the observation that intrahippocampal topiramate (TPM) administration does not suppress limbic seizures in the focal pilocarpine model, we investigated the role of the SNR in the anticonvulsant mechanism of action of TPM. METHODS: Limbic seizures were evoked in freely moving rats by intrahippocampal administration of pilocarpine via a microdialysis probe. Changes in hippocampal extracellular (EC) glutamate and GABA concentrations were monitored. Effects of intraperitoneal (10-200 mg/kg), intrahippocampal (1-5 mM), and bilateral intranigral (100-300 nmol) TPM administration on pilocarpine-induced seizures and neurochemical changes were evaluated. Effects of TPM administration alone on hippocampal and nigral EC amino acid concentrations were also studied. RESULTS: Systemic and intranigral, but not intrahippocampal TPM administration suppressed pilocarpine-induced seizures and neurochemical changes. Nigral GABA(A) receptor blockade by picrotoxin abolished the anticonvulsant effect of TPM in SNR. Systemic TPM administration increased hippocampal glutamate and decreased GABA. Intranigral TPM administration increased hippocampal glutamate, but not GABA. Intrahippocampal TPM increased hippocampal glutamate and GABA, but only at high concentrations. CONCLUSIONS: In the focal pilocarpine model, TPM does not exert its anticonvulsant effect at the site of seizure initiation. We identified the SNR as a site of action of TPM, and showed that the nigral GABA-ergic system is central to TPM's anticonvulsant effect in SNR. Anticonvulsant effects and neurochemical changes in hippocampus following intranigral TPM administration suggest the existence of a nigro-hippocampal circuit, which may be involved in the control of limbic seizures.

Animals↗

In vitro investigations on the effect of pilocarpine on the metabolism in pig lenses illustrated with some intermediate metabolites.

22 pairs of pig lenses were incubated in TCM 199 5 g, with pilocarpine 5 X 10(-4) M and 10(-2) M. 5 X 10(-4) M is the probable concentration in the aqueous during ordinary pilocarpine medication. The concentration of 1-lactate, pyruvate, RTP, RDP and AMP was determined in the lenses and the assimilation of glucose and the production of 1-lactate and pyruvate were measured. As far as pilocarpine 5 X 10(-4) M was concerned no significant differences were found, but pilocarpine 10(-2) M gave a significantly higher 1-lactate concentration in the lenses (118%) and increased the assimilation of glucose to 120% and also augmented the production of 1-lactate to 168% and the pyruvate to 184%, tending to show that pilocarpine 10(-2) M increased the glycolytic activity in the lenses. The concentrations of RTP, RDP and AMP were unchanged.

Adenosine Diphosphate↗

One-month crossover trial comparing the intraocular pressure control of 3.4% Piloplex twice daily with 2.0% pilocarpine four times daily.

A one-month crossover trial comparing Piloplex 3.4% b.i.d. with pilocarpine 2.0% q.i.d. was conducted to compare the effectiveness of the 2 drugs in reducing the intraocular pressure of ocular hypertensive and open-angle glaucoma in subjects previously controlled with pilocarpine 2.0%. For both groups the mean IOP increased slightly from baseline with pilocarpine and decreased significantly from baseline with Piloplex. The side effects of both treatments were minor. Piloplex and pilocarpine treatment were both associated with eye dryness; Piloplex was associated with lacrimation in 2 subjects. This controlled study showed that Piloplex 3.4% b.i.d. was more effective than pilocarpine 2% q.i.d. in lowering intraocular pressure.

Adult↗

Individual responsiveness to topical pilocarpine and the effects of variations in application technique.

The effects of nasolacrimal obstruction (NLO) and of eyelid closure (EC) were studied in a group of 6 healthy female subject (25-29 years). The aim was to determine the best application technique for patients. NLO or EC for 1 min was assumed to be a maximum time for patient compliance. A standard eye drop bottle was used with a drop volume of about 40 microliter. One drop of a 1% pilocarpine solution was instilled into the lower conjunctival sac of one eye in a randomized manner: a) NLO b) EC c) NLO and EC d) neither NLO nor EC. The effects on the pupil size, static refraction for distance and accommodative power were followed for 2 h. The results showed no significant difference between the 4 techniques. Pronounced interindividual differences but only small intraindividual differences were found in this group of healthy young females. Two subjects always responded strongly, and 2 other subjects always did so weakly. The application of the same amount of pilocarpine ointment (3%) increased and prolonged the effects on pupil size, refraction and accommodation at all points of time without reaching statistical significance compared with eye drops. Pilocarpine ointment caused considerable subjective discomfort. The experiments with pilocarpine suggest that, from a practical point of view, different techniques of application of ocular drugs seem to be a little importance with regard to local effect. The possibility of pronounced individual differences in pharmacological response should be borne in mind. Pilocarpine induced a significant increase in accommodative power.

Accommodation, Ocular↗